Microenvironment on Demand: A breakthrough technology for personalized cell therapy discoveries

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Chief Scientific Officer, Scribe Biosciences
    Biography
      After post-doctoral work at Johns Hopkins University Medical School, Dr. Srinivasan started out as an entry-level scientist in CuraGen and conceived a process to normalize and sequence expressed sequence tags for multiple tissues. The database of sequence tags was then used in conjunction with an in-house differential gene expression technology to identify novel, therapeutically-relevant proteins/targets, at least one of which is in advanced clinical trials (Glembatumumab vedotin, Celldex Therapeutics). Starting 2000 to 2008, Dr. Srinivasan held various positions to launch the first next generation DNA-sequencer, Roche/454 GS20. Two generations of sequencers later, Dr. Srinivasan co-lead the effort to sequence the first human genome using next generation DNA sequencing. Starting 2008, Dr. Srinivasan was head of Global Genomics R and D at Agilent Technologies where he oversaw the launch of 70+ products/product extensions. Dr. Srinivasan joined WaferGen as Chief Technology Officer where he conceived the idea to repurpose WaferGen's SmartChip technology to perform single-cell genomics and lead the development of both the ICELL8 system as well as the alpha prototype of the SMARTer ICELL8-CX system. WaferGen was subsequently acquired by Takara Bio USA in March 2017. Dr. Srinivasan currently is Chief Scientific Officer at Scribe Biosciences. Dr. Srinivasan graduated with a Ph.D. from Colorado State University.

    Abstract

    NCI estimates that cancer will be the leading cause of death in 2030, worldwide.  Checkpoint inhibitors and adoptive cell therapies (ACTs) cost up to ~$2 million/patient and have shown durable responses in a few patients while many patients experience life-threatening side-effects. So, there is a critical need to identify cost-effective therapies to treat cancer with minimal to no side-effects.  Deep mapping of cancer antigens and their cognate immune cells is one approach that has the potential for more universal/targeted treatment. However, no methods exist that can identify cancer antigens and their cognate immune cells functionally and link phenotypic readouts to antigen and immune cell DNA sequences, 100k-1M cell combinations at a time. We will show proof-of-concept for the MOD platform that integrates three technologies after fluorescently-labeled single-cells are encapsulated in droplets – droplet-based cell-sorting and merging, single-cell-based interferon-gamma assays and selective sequencing of T-cell receptor variable regions based on interferon-gamma signals.

    Learning Objectives:

    1. Importance of linked neoantigen/TCR sequence information

    2. Microenvironment on demand technology’s role in screening for adoptive cancer cell therapies (T-cell and CAR-Ts)


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    Loading Comments...
    Show Resources